Ripasudil enhances aqueous humour outflow through the trabecular meshwork, while Timolol reduces aqueous humour production

Akums Drugs & Pharmaceuticals has launched Ripasudil-Timolol combination therapy for glaucoma treatment. The DCGI-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO to receive approval for this innovative formulation.

The new combination therapy offers a dual mechanism of action for superior intraocular pressure (IOP) control: Ripasudil enhances aqueous humour outflow through the trabecular meshwork, while Timolol reduces aqueous humour production. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments.

Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals, states, "This innovation integrates two distinct mechanisms of action to improve glaucoma treatment. By enhancing efficacy and ease of use, we aim to offer a more practical and patient-friendly solution. Our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected. With a patient-first approach and a commitment to Make in India, we continue to develop solutions that are of high-quality, and aligned with global standards. 

The single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management—patient adherence. By combining two medications into one product, patients benefit from enhanced convenience and potentially improved compliance.

"With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial," added Sandeep Jain, MD, Akums Drugs & Pharmaceuticals. "This launch marks a significant step in making high-quality and effective treatment more accessible."

Akums will utilise its state-of-the-art manufacturing facilities to ensure consistent supply and the broad availability of this breakthrough therapy. With approximately 11.9 million people affected by glaucoma in India, this innovative combination addresses a critical healthcare need by providing an effective solution that simplifies treatment while potentially improving outcomes.